The forecast for this winter’s respiratory season is, on paper, unremarkable. CDC expects a season roughly like last year’s. For anyone who manages hospital supply, that word “normal” deserves a second look.

A normal season used to be something the system could absorb. Going into 2026–2027, drug shortages continue to climb, with more of them hinging on a single manufacturer, and pediatric care is concentrating into fewer hospitals. The demand side looks familiar. The supply side has less slack than it did a year ago. The biggest risk this winter is not a severe respiratory season, but an ordinary one meeting a supply chain with fewer backups.

CDC’s 2026–2027 Respiratory Disease Season Outlook, expects combined COVID-19, flu and RSV hospitalizations to peak within 20% of last season’s peak. Flu is expected to be moderate. RSV is expected to look like 2025–2026, which peaked unusually late, in February.

The detail that matters for supply is timing. CDC expects the three viruses to peak in overlapping windows from December through February. COVID typically peaks around late December, flu anywhere from December to February, and RSV may run late again. If a new COVID variant emerges, CDC’s alternate scenario pushes that peak to late January, right on top of flu and RSV. Overlapping peaks mean overlapping demand: antibiotics, antivirals, inhaled medications, IV fluids and respiratory supplies all get pulled at once, often from the same distributors. Meanwhile, the supply side is moving in the opposite direction.

Active U.S. drug shortages reached 227 in the second quarter of 2026, the third straight quarterly increase. Antimicrobials rank among the most affected drug classes, behind only central nervous system medications. Two details stand out:

• Sole-source risk: 48% of new 2026 shortages involve products made by a single manufacturer. One quality problem or line shutdown takes the whole national supply with it.
• Low visibility: Manufacturers listed the cause of 59% of 2025 shortages as “unknown” or declined to give one. Supply teams are planning around disruptions they can’t see coming.

Underneath both is the economics of generics. Thin margins leave little incentive to hold safety stock or add capacity. Respiratory season also shows how quickly demand can outrun supply. The last time it surged sharply, in 2022, Vizient data showed hospital demand for amoxicillin jumped 43% in a single month, from September to October, while supplier fill rates fell 25%.

Those pressures land hardest on pediatrics. As of July, 16 pediatric drugs were in active shortage, and six of them were IV fluids and additives. Oral liquids like furosemide and chlorothiazide are on the list too. Liquid formulations are harder to make and have fewer suppliers, so when they run short, hospital pharmacies fall back on compounding or dilution.

Pediatric hospitals also have fewer neighbors to lean on. As one pharmacy director told Becker’s, “there are not too many pediatric hospitals to network together, or to borrow medication from.” That network is shrinking. In 2026, the University of Kansas Health System moved to close its pediatric ICU, sending those patients to Children’s Mercy. Providence Santa Rosa and a St. Joseph’s hospital in suburban Chicago closed inpatient pediatric units. Low census makes those closures sensible most of the year. In a surge, it means demand and supply needs pile up at fewer regional hubs.

Beyond the bedside, this season arrives amid policy changes that touch supply directly. The first is a countdown on generic drug tariffs. In July, the administration announced tariffs on imported generics: 0% until 2028, then 100%, then 200% from 2029. About 80% of the active ingredients used in U.S. drugs come from China and India, and analysts warn some low-margin makers may exit rather than absorb the cost. The tariffs don’t take effect this winter, but this is the last respiratory season before they do, and manufacturers’ decisions about which generics are worth making will be shaped in the meantime.

Other costs are already rising. China-sourced medical gloves now carry a 100% duty, masks and respirators 50%, and syringes and needles 100%. Children’s hospitals face budget pressure as well: most get more than half their patient revenue from Medicaid, and the 2025 tax package projects about $1 trillion in Medicaid reductions over 10 years. None of these pressures peaks this winter, but together they shape how much buffer the system can carry into it.

A moderate season won’t make headlines on its own. The signals worth tracking are on the supply side: whether the ASHP shortage count rises for a fourth straight quarter, whether new shortages appear in antimicrobials, oral liquids and IV fluids as the December–February overlap arrives, how regional pediatric hubs absorb volume from closed units nearby, and whether manufacturers and distributors start moving inventory ahead of the 2028 tariff date.

The forecast tells us demand should look familiar. If supply gives way this winter, the data so far points to sole-source products and pediatric formulations as the first places it will show. The open question is whether a system with less slack can meet a normal season.